That headline-making study that reports that one shot of H1N1 vaccine appears to provide sufficient protection has a Triangle connection.
Australian shot maker CSL Ltd., which performed the study featured in The New England Journal of Medicine, is a client of Durham-based Quintiles Transnational and acknowledges Quintiles' contributions at the conclusion of the published article.
Quintiles spokesman Phil Bridges said in an e-mail message that the company can't go into specifics, but it can say it is providing "a full scope of services to CSL on trials of their H1N1 vaccine."
Those services include project and data management, biostatistics and "medical writing," Bridges said.
The study is significant because it means the H1N1 vaccine supply could go twice as far as was previously predicted, since up to now it was expected that people would need two shots.
Durham-based Quintiles Transnational is a pharmaceutical services company that employs 23,000 worldwide, including more than 1,400 in the Triangle.